PREDICT-1 Randomization Complete: Enrichment Confirms but No Data Yet

What happened

Oculis announced the completion of randomization in PREDICT-1, its registrational trial of Licaminlimab for TNFR1-mediated dry eye disease, with 176 patients enrolled and two-thirds carrying the target genetic variant linked to enhanced response in Phase 2. This milestone validates the company's ability to execute its precision-medicine strategy, but it provides no efficacy data, leaving the key binary risks unchanged. The master report already assigns a 'POTENTIAL SELL' rating with conviction 3.5, driven by high expectations around OCS-01's DIAMOND readout in 2Q26 and the cash burn from three concurrent registrational programs. While enriched enrollment may improve the odds of PREDICT success, the trial's outcome remains years away, and the company's dilution risk persists despite a guided runway into 2029. Overall, this operational update is marginally positive but unlikely to alter the fundamental risk-reward at current levels.

Implication

Investors should treat this as operational progress rather than a value inflection. The enriched enrollment could enhance the probability of PREDICT success, but the trial's topline is not expected until well after DIAMOND's binary readout in 2Q26, which remains the primary driver. With the stock trading at $23.25 and a market cap of $1.2B, the market already prices substantial upside across all three assets, leaving little room for error. The company's cash runway into 2029 is contingent on avoiding major scope creep or regulatory setbacks, and any disappointment in DIAMOND could trigger a sharp de-rating. Therefore, we maintain a cautious stance: await pullback below $16 or de-risking data before adding.

Thesis delta

The completion of PREDICT-1 randomization with high-responder enrichment is consistent with prior expectations and does not alter our valuation framework. The core thesis remains that OCS-01 DIAMOND data is the primary catalyst, and PREDICT's progress, while encouraging, is insufficient to offset the current high expectations and downside skew. Accordingly, we maintain our 'POTENTIAL SELL' rating and await either a material pullback or definitive positive data.